{"disease":{"id":"refractory-or-relapsed-multiple-myeloma","name":"refractory or relapsed multiple myeloma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06952478","title":"A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":486,"lead_sponsor_name":"Celltrion","has_results":false},{"nct_id":"NCT06119685","title":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"Indapta Therapeutics, INC.","has_results":false},{"nct_id":"NCT03090659","title":"LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Nanjing Legend Biotech Co.","has_results":false},{"nct_id":"NCT07523555","title":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT03755154","title":"Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":60,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT03716856","title":"Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":11,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT03674463","title":"LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Second Affiliated Hospital of Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT03380039","title":"Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma","phase":"NA","overall_status":"UNKNOWN","enrollment_count":6,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}